An Open-label Trial Investigating the Association Between Nocturia and Sleep During 12 Weeks of Treatment with Desmopressin Orally Disintegrating Tablet (ODT) for Nocturia due to Nocturnal Polyuria in Adults
Phase of Trial: Phase III
Latest Information Update: 03 Oct 2018
At a glance
- Drugs Desmopressin (Primary)
- Indications Nocturia
- Focus Therapeutic Use
- Acronyms AWAKEN
- Sponsors Ferring Pharmaceuticals
- 28 Sep 2018 This trial was completed in Netherlands (end date: 2018-07-13), according to European Clinical Trials Database.
- 22 Aug 2018 This trial was completed in Hungary (end date: 2018-07-13), according to European Clinical Trials Database.
- 17 Nov 2017 New trial record